Karen R. Jacobson, MD, MPH
Assistant Professor
Boston University School of Medicine
Dept of Medicine
Infectious Diseases

MD, Johns Hopkins University School of Medicine
MPH, Harvard School of Public Health



Dr. Karen Jacobson is an Assistant Professor of Medicine in the Section of Infectious Diseases, Boston University School of Medicine, with a secondary appointment in the Department of Epidemiology, Boston University School of Public Health. Dr. Jacobson’s research focuses on the epidemiology of drug resistant tuberculosis, including identification of social, biological, and economic determinants of and risk factors for drug resistance and approaches for improving TB outcomes in resource-limited settings. Dr. Jacobson has established a highly productive collaboration with researchers at Stellenbosch University in Cape Town, South Africa, investigating the drivers of drug resistance in the Western Cape Province of South Africa and working to identify potentially modifiable factors.

Assistant Professor
Boston University School of Public Health
Epidemiology





The impact of alcohol consumption on TB treatment outcomes
04/08/2016 - 03/31/2021 (PI)
NIH-NIAID
1R01AI119037-01A1

URBAN ARCH (3/5) Uganda Cohort- TB prevention therapy for HIV-infected alcohol drinkers in Uganda…
09/22/2016 - 08/31/2018 (PI)
The Regents of the University of California NIH-NIAAA

Lifespan/Tufts/Brown Center for AIDS Research(CFAR): SWG1
07/01/2017 - 06/30/2018 (PI)
Miriam Hospital NIH-NIAID

ASTMH Fellowship in Tropical Infectious Diseases
02/01/2013 - 06/30/2018 (PI)
American Society of Tropical Medicine and Hygiene

Phase 2 Pharmacodynamic Study of Hidh-dose Levofloxacin in MDR-TB Treatment
01/01/2015 - 07/31/2017 (PI)
Trustees of Boston University NIH-NIAID

Geospatial clustering and molecular and social epidemiology of drug resistant TB
08/01/2013 - 12/31/2016 (PI)
NIH-FIC
5K01TW009213-6



Yr Title Project-Sub Proj Pubs
2017 The impact of alcohol consumption on TB treatment outcomes 5R01AI119037-02
2016 The impact of alcohol consumption on TB treatment outcomes 1R01AI119037-01A1
2015 Geospatial clustering and molecular and social epidemiology of drug resistant TB 5K01TW009213-06 4
2014 Geospatial clustering and molecular and social epidemiology of drug resistant TB 5K01TW009213-05 4
2013 Geospatial clustering and molecular and social epidemiology of drug resistant TB 5K01TW009213-04 4
2012 Geospatial clustering and molecular and social epidemiology of drug resistant TB 7K01TW009213-03 4
2012 Geospatial clustering and molecular and social epidemiology of drug resistant TB 5K01TW009213-02 4
2011 Geospatial clustering and molecular and social epidemiology of drug resistant TB 1K01TW009213-01 4
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

  1. Freiman JM, Jacobson KR, Muyindike WR, Horsburgh CR, Ellner JJ, Hahn JA, Linas BP. Isoniazid Preventive Therapy for People With HIV Who Are Heavy Alcohol Drinkers in High TB-/HIV-Burden Countries: A Risk-Benefit Analysis. J Acquir Immune Defic Syndr. 2018 Apr 01; 77(4):405-412.View Related Profiles. PMID: 29239900.
     
  2. Fregonese F, Ahuja SD, Akkerman OW, Arakaki-Sanchez D, Ayakaka I, Baghaei P, Bang D, Bastos M, Benedetti A, Bonnet M, Cattamanchi A, Cegielski P, Chien JY, Cox H, Dedicoat M, Erkens C, Escalante P, Falzon D, Garcia-Prats AJ, Gegia M, Gillespie SH, Glynn JR, Goldberg S, Griffith D, Jacobson KR, Johnston JC, Jones-López EC, Khan A, Koh WJ, Kritski A, Lan ZY, Lee JH, Li PZ, Maciel EL, Galliez RM, Merle CSC, Munang M, Narendran G, Nguyen VN, Nunn A, Ohkado A, Park JS, Phillips PPJ, Ponnuraja C, Reves R, Romanowski K, Seung K, Schaaf HS, Skrahina A, Soolingen DV, Tabarsi P, Trajman A, Trieu L, Banurekha VV, Viiklepp P, Wang JY, Yoshiyama T, Menzies D. Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis. Lancet Respir Med. 2018 Apr; 6(4):265-275. PMID: 29595509.
     
  3. Brooks-Pollock E, Jacobson KR. Rethinking tuberculosis control by targeting previously treated individuals. Lancet Glob Health. 2018 04; 6(4):e361-e362. PMID: 29472017.
     
  4. Farhat MR, Jacobson KR, Franke MF, Kaur D, Murray M, Mitnick CD. Fluoroquinolone Resistance Mutation Detection Is Equivalent to Culture-Based Drug Sensitivity Testing for Predicting Multidrug-Resistant Tuberculosis Treatment Outcome: A Retrospective Cohort Study. Clin Infect Dis. 2017 Oct 15; 65(8):1364-1370. PMID: 29017248.
     
  5. Jacobson KR, Barnard M, Kleinman MB, Streicher EM, Ragan EJ, White LF, Shapira O, Dolby T, Simpson J, Scott L, Stevens W, van Helden PD, Van Rie A, Warren RM. Implications of Failure to Routinely Diagnose Resistance to Second-Line Drugs in Patients With Rifampicin-Resistant Tuberculosis on Xpert MTB/RIF: A Multisite Observational Study. Clin Infect Dis. 2017 Jun 01; 64(11):1502-1508.View Related Profiles. PMID: 28199520; DOI: 10.1093/cid/cix128;.
     
  6. Jacobson KR. Tuberculosis. Ann Intern Med. 2017 Feb 07; 166(3):ITC17-ITC32. PMID: 28166561; DOI: 10.7326/AITC201702070;.
     
  7. Farhat MR, Sultana R, Iartchouk O, Bozeman S, Galagan J, Sisk P, Stolte C, Nebenzahl-Guimaraes H, Jacobson K, Sloutsky A, Kaur D, Posey J, Kreiswirth BN, Kurepina N, Rigouts L, Streicher EM, Victor TC, Warren RM, van Soolingen D, Murray M. Genetic Determinants of Drug Resistance in Mycobacterium tuberculosis and Their Diagnostic Value. Am J Respir Crit Care Med. 2016 Sep 01; 194(5):621-30.View Related Profiles. PMID: 26910495; PMCID: PMC5027209; DOI: 10.1164/rccm.201510-2091OC;.
     
  8. Farhat MR, Jacobson KR, Franke MF, Kaur D, Sloutsky A, Mitnick CD, Murray M. Gyrase Mutations Are Associated with Variable Levels of Fluoroquinolone Resistance in Mycobacterium tuberculosis. J Clin Microbiol. 2016 Mar; 54(3):727-33. PMID: 26763957; PMCID: PMC4767988; DOI: 10.1128/JCM.02775-15;.
     
  9. Jacobson KR, Sabin LL. Scaling up multidrug-resistant tuberculosis care in China. Lancet Glob Health. 2015 Apr; 3(4):e183-4.View Related Profiles. PMID: 25794667; PMCID: PMC4492310; DOI: 10.1016/S2214-109X(15)70093-8;.
     
  10. Farhat MR, Mitnick CD, Franke MF, Kaur D, Sloutsky A, Murray M, Jacobson KR. Concordance of Mycobacterium tuberculosis fluoroquinolone resistance testing: implications for treatment. Int J Tuberc Lung Dis. 2015 Mar; 19(3):339-41. PMID: 25686144; PMCID: PMC4486051; DOI: 10.5588/ijtld.14.0814;.
     
Showing 10 of 20 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 20 publications over 10 distinct years, with a maximum of 3 publications in 2013 and 2017 and 2018

YearPublications
19992
20021
20101
20111
20122
20133
20152
20162
20173
20183
In addition to these self-described keywords below, a list of MeSH based concepts is available here.

alcohol
drug resistant tuberculosis
global health
spatial mapping
tuberculosis
Contact for Mentoring:


771 Albany St
Boston MA 02118
Google Map

617.414.5213
Download vCard

Jacobson's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
See all (92) concept(s)
_
Co-Authors
See all (6) people
_
Similar People
See all (60) people
_
Same Department
Search Department